Though mutations or methylation of RAD51 and ATM alterations were identified associated with PARPi responses in ovarian cancer patients [44, 45], the extent to which other candidate HRR related genes impact PARPi response is still under investigation. This evidence concerns the gene RAD51 and ovarian cancer.